Executive Change in Control and Severance Benefit Plan (February 23rd, 2016)
The Jazz Pharmaceuticals plc Amended and Restated Executive Change in Control and Severance Benefit Plan (the "Plan") was originally established effective as of May 1, 2007 (the "Effective Date") and was amended and restated effective as of February 17, 2009, October 24, 2011, February 14, 2012, April 24, 2012, July 31, 2013 and February 10, 2016.
2015 Executive Officer Compensation Arrangements (May 7th, 2015)
2015 Base salary rates generally effective by March 1, 2015. Dr. Smith's base salary rate is effective beginning on April 13, 2015, the commencement date of her employment.
Named Officer 2015 Target Bonus Opportunity (February 18th, 2015)
Mr. Cozadd's target bonus percentage of 100% was previously established and unchanged as a result of the February 11, 2015 modifications to the target bonus opportunity levels under the Bonus Plan.
2014 Executive Officer Compensation Arrangements (May 8th, 2014)
2014 Base salary rates generally effective by March 1, 2014. Mr. Keegan's base salary is paid in Euro and is EU275,000 for 2014. This conversion to U.S. dollars was calculated based on the average monthly exchange rate for December 2013 as reported by the OANDA Corporation. Mr. Young's base salary rate is effective beginning on March 9, 2014, the effective date of his appointment as Chief Financial Officer. Prior to March 9, 2014, Mr. Young's 2014 base salary rate was $360,500.
Jazz Pharmaceuticals Plc Amended and Restated Executive Change in Control and Severance Benefit Plan (November 5th, 2013)
2013 Executive Officer Compensation Arrangements (May 7th, 2013)
Target bonus percentage for each officer is based on his or her position and/or responsibility level as provided in Jazz Pharmaceuticals plc's cash bonus plans.
Dated 9th November, 2012 SURRENDER of Lease of 45 Fitzwilliam Square, Dublin 2 a & L GOODBODY (February 26th, 2013)
JAZZ PHARMACEUTICALS PLC (formerly known as Azur Pharma Limited) having its registered office at 4th Floor, Connaught House, 1 Burlington Road, Dublin 4 (hereinafter called the Tenant which expression shall where the context so admits or requires include the Tenant's successors) of the one part; and
Escrow Agreement (January 18th, 2012)
THIS ESCROW AGREEMENT (Agreement) is made and entered into as of January 18, 2012, by and among: JAZZ PHARMACEUTICALS PLC (f/k/a Azur Pharma Limited) a public limited company formed under the laws of Ireland (registered number 504402) whose registered address is 45 Fitzwilliam Square, Dublin 2, Ireland (Company); JAZZ PHARMACEUTICALS, INC. (Jazz, Inc.); Seamus Mulligan, as representative (the Indemnitors Representative) of certain shareholders of the Company; and DEUTSCHE BANK NATIONAL TRUST COMPANY, a national banking association (the Escrow Agent). Capitalized terms used in this Agreement and not otherwise defined shall have the meanings given to them in the Merger Agreement, a copy of which has been delivered to the Escrow Agent solely for allowing the Escrow Agent access to the definitions set forth therein.
Form of Voting Agreement (September 19th, 2011)
THIS VOTING AGREEMENT (Voting Agreement) is entered into as of September 19, 2011, by and among AZUR PHARMA LIMITED, a private limited company incorporated in Ireland (Azur), JAZZ PHARMACEUTICALS, INC., a Delaware corporation (the Company) and (Stockholder).
Subscription Agreement (July 16th, 2008)